newsfilter
← Latest News
GlobeNewswire·

Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies

TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.TTI-622 monotherapy shows 6/18...